• 제목/요약/키워드: Chronic heart failure

검색결과 123건 처리시간 0.025초

혈액투석 환자의 동정맥루 천자 시 피부자극법과 국소마취크림 도포에 따른 통증과 심박변이도 비교 (Comparison of Skin Stimulation Method and Topical Anesthetic Cream on Pain and Heart Rate Variability during Arteriovenous Fistula Puncture in Hemodialysis Patients)

  • 강효영;채영란
    • Journal of Korean Biological Nursing Science
    • /
    • 제21권3호
    • /
    • pp.207-216
    • /
    • 2019
  • Purpose: The purpose of this was to compare effects of application of the skin stimulation method and topical anesthetic cream on pain, heart rate variability and satisfaction according to nursing intervention methods during arteriovenous fistula puncture in chronic renal failure hemodialysis patients. Methods: This study was a crossover design. Participants were 36 patients with chronic renal failure receiving hemodialysis treatment. Two forms of intervention were applied to participants, and then pain and heart rate variability were measured during the puncture. Results: There were no statistically significant differences according to each treatment in vein pain and artery pain. Also, there were no statistically significant differences according to each treatment in stress index, sympathetic activity (LF), parasympathetic activity (HF) and sympathetic activity/parasympathetic activity (LF/HF ratio). Satisfaction with application of skin stimulation method was statistically higher than that of topical anesthetic cream application. Conclusion: This suggests that application of the skin stimulation method complements disadvantages of topical anesthetic cream application and demonstrates possibility of application as a nursing intervention method which can be conveniently used by nurses in clinical practice.

Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure

  • Sang Min Park;Soo Youn Lee;Mi-Hyang Jung;Jong-Chan Youn;Darae Kim;Jae Yeong Cho;Dong-Hyuk Cho;Junho Hyun;Hyun-Jai Cho;Seong-Mi Park;Jin-Oh Choi;Wook-Jin Chung;Seok-Min Kang;Byung-Su Yoo;Committee of Clinical Practice Guidelines, Korean Society of Heart Failure
    • Korean Circulation Journal
    • /
    • 제53권7호
    • /
    • pp.425-451
    • /
    • 2023
  • Most patients with heart failure (HF) have multiple comorbidities, which impact their quality of life, aggravate HF, and increase mortality. Cardiovascular comorbidities include systemic and pulmonary hypertension, ischemic and valvular heart diseases, and atrial fibrillation. Non-cardiovascular comorbidities include diabetes mellitus (DM), chronic kidney and pulmonary diseases, iron deficiency and anemia, and sleep apnea. In patients with HF with hypertension and left ventricular hypertrophy, renin-angiotensin system inhibitors combined with calcium channel blockers and/or diuretics is an effective treatment regimen. Measurement of pulmonary vascular resistance via right heart catheterization is recommended for patients with HF considered suitable for implantation of mechanical circulatory support devices or as heart transplantation candidates. Coronary angiography remains the gold standard for the diagnosis and reperfusion in patients with HF and angina pectoris refractory to antianginal medications. In patients with HF and atrial fibrillation, longterm anticoagulants are recommended according to the CHA2DS2-VASc scores. Valvular heart diseases should be treated medically and/or surgically. In patients with HF and DM, metformin is relatively safer; thiazolidinediones cause fluid retention and should be avoided in patients with HF and dyspnea. In renal insufficiency, both volume status and cardiac performance are important for therapy guidance. In patients with HF and pulmonary disease, beta-blockers are underused, which may be related to increased mortality. In patients with HF and anemia, iron supplementation can help improve symptoms. In obstructive sleep apnea, continuous positive airway pressure therapy helps avoid severe nocturnal hypoxia. Appropriate management of comorbidities is important for improving clinical outcomes in patients with HF.

심부전 모델에서 실험적 심근성형술의 단기 혈역학적 효과에 관한 연구 (Study on the Short-Term Hemodynamic Effects of Experimental Cardiomyoplasty in Heart Failure Model)

  • 정윤섭;염욱;이창하;김욱성;이영탁;김원곤
    • Journal of Chest Surgery
    • /
    • 제32권3호
    • /
    • pp.224-236
    • /
    • 1999
  • 배경: 역동적 심근성형술에서 골격근 수축에 의한 단기 혈역학적 변화를 관찰하고 이에 미치는 인자를 분석하고자 하였다. 대상 및 방법: 이를 위해 20-30kg 사이의 한국산 잡견 10마리를 두 그룹으로 나눠 심장 상태를 정상과 심부전 상태로 구분하였고 골격근 상태도 활성도 및 수축력의 차이가 나도록 구분하였다. 그룹 A에서는 5마리의 정상 심장상태의 실험견에 심근성형술을 시행한 뒤 8주후 혈역학 검사를 실시하였고, 그룹 B에서는 5마리의 실험견에 8주동안 매주 1 mg/kg의 doxorubicin을 주입하여 만성 심부전 상태를 만들면서 동시에 좌측 광배근의 사전 조건화를 위한 근육훈련을 한후 심근성형술을 시행하고 바로 혈역학 검사를 실시하였다. 결과: 그룹 A의 정상 심장 상태에서 광배근 수축으로 평균 우심방 압력을 제외한 나머지 좌심실 혈역학 지수에는 유의한 변화가 없었다. 그룹 B에서는 광배근 수축으로 심박출량(cardiac output; CO)은 16.7$\pm$7.2%, 좌심실 압력발생 속도(positive pressure development rate of left ventricle; dp/dt)는 9.3$\pm$3.2%, 일회 심박출량(stroke volume; SV)은 16.8$\pm$8.6%, 좌심실 박출작업량(left ventricular stroke work; SW)은 23.1$\pm$9.7% 증가하였고, 좌심실 이완기말압(left ventricular end-diastole pressure; LVEDP)은 32.1$\pm$4.6%, 평균 폐동맥쐐기압(mean pulmonary capillary wedge pressure; mPCWP)은 17.7$\pm$9.1% 감소하였다(p<0.05). 그러나 그룹 A에서 imipramine을 7.5 mg/kg/hour의 속도로 34$\pm$2.6분 투여하여 CO이 17.5$\pm$2.7%, 좌심실 수축기압(left ventricular systolic pressure)이 15.8$\pm$2.5% 감소하고 LVEDP가 54.3$\pm$15.2% 증가한 일시적 급성 심부전 상태를 유도한 뒤(p<0.05), 이 상태에서 광배근을 자극하였더니 CO은 4.5$\pm$1.8%, dp/dt는 3.1$\pm$1.1%, SV는 5.7$\pm$3.6%, SW는 6.9$\pm$4.4% 증가하였고, LVEDP는 11.7$\pm$4.7% 감소하였다(p<0.05). 그룹 A의 급성 심부전 상태와 그룹 B의 만성 심부전 상태에서 모두 광배근 수축으로 변화한 CO, dp/dt, SV, SW, LVEDP 같은 좌심실 혈역학 지표들의 변화의 폭을 비교하면 그룹 B에서 그룹 A에서보다 더 컸다(p<0.05). 그룹 A에서 유도된 급성 심부전 상태와 그룹 B의 만성 심부전 상태가 CO, dp/dt, SV, SW, LVEDP 같은 좌심실 혈역학 지표들 면에서 통계학적으로 차이가 없고(p>0.05), 육안적으로 광배근을 관찰하였을 때 그룹 A에서는 광배근의 유착 및 염증소견이 모두에서 있었고 그중 2마리에서는 광배근의 수축을 목격할 수 없었던 반면, 그룹 B에서는 5마리 모두에서 광배근이 활발하게 수축하였다는 점을 함께 고려하면 그룹 B에서의 더 큰 증폭 효과가 광배근의 활성도 및 수축력의 차이로부터 기인한다고 평가할 수 있다. 결론: 이상에서 역동적 심근성형술의 수축기 혈역학적 변화는 심부전 상태에서만 긍정적인 개선 효과를 나타내며, 그 효과의 극대화를 위해서는 근육의 수축력을 유지하는 것이 매우 중요함을 알 수 있다.

  • PDF

KR-39038, a Novel GRK5 Inhibitor, Attenuates Cardiac Hypertrophy and Improves Cardiac Function in Heart Failure

  • Lee, Jeong Hyun;Seo, Ho Won;Ryu, Jae Yong;Lim, Chae Jo;Yi, Kyu Yang;Oh, Kwang-Seok;Lee, Byung Ho
    • Biomolecules & Therapeutics
    • /
    • 제28권5호
    • /
    • pp.482-489
    • /
    • 2020
  • G protein-coupled receptor kinase 5 (GRK5) has been considered as a potential target for the treatment of heart failure as it has been reported to be an important regulator of pathological cardiac hypertrophy. To discover novel scaffolds that selectively inhibit GRK5, we have identified a novel small molecule inhibitor of GRK5, KR-39038 [7-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-2-(2-chlorophenyl)-6-fluoroquinazolin-4(3H)-one]. KR-39038 exhibited potent inhibitory activity (IC50 value=0.02 µM) against GRK5 and significantly inhibited angiotensin II-induced cellular hypertrophy and HDAC5 phosphorylation in neonatal cardiomyocytes. In the pressure overload-induced cardiac hypertrophy mouse model, the daily oral administration of KR-39038 (30 mg/kg) for 14 days showed a 43% reduction in the left ventricular weight. Besides, KR-39038 treatment (10 and 30 mg/kg/day, p.o.) showed significant preservation of cardiac function and attenuation of myocardial remodeling in a rat model of chronic heart failure following coronary artery ligation. These results suggest that potent GRK5 inhibitor could effectively attenuate both cardiac hypertrophy and dysfunction in experimental heart failure, and KR-39038 may be useful as an effective GRK5 inhibitor for pharmaceutical applications.

급성 우심 부전의 집중 치료 (Intensive management of acute right heart failure)

  • 김기범;노정일
    • Clinical and Experimental Pediatrics
    • /
    • 제50권11호
    • /
    • pp.1041-1048
    • /
    • 2007
  • Not a few patients in children and adolescents are suffering from right ventricular (RV) dysfunction resulting from various conditions such as chronic lung disease, left ventricular dysfunction, pulmonary hypertension, or congenital heart defect. The RV is different from the left ventricle in terms of ventricular morphology, myocardial contractile pattern and special vulnerability to the pressure overload. Right ventricular failure (RVF) can be evaluated in terms of decreased RV contractility, RV volume overload, and/or RV pressure overload. The management for RVF starts from clear understanding of the pathophysiology of RVF. In addition to correction of the underlying disease, management of RVF per se is very important. Meticulous control of volume status, inotropic agents, vasopressors, and pulmonary selective vasodilators are the main tools in the management of RVF. The relative importance of each tool depends on the individual clinical status. Medical assist device and surgery can be considered selectively in case of refractory RVF to optimal medical treatment.

이첨판 패쇄부전증에 이환된 개에서 NT-proBNP농도, 비만, 당 관련 인자 및 지방 관련인자간에 상관관계에 대한 연구 (Relationships between NT-proBNP and Obesity, Glucose and Lipid Profiles in Dogs with Chronic Mitral Valve Insufficiency)

  • 이승곤;남효승;현창백
    • 한국임상수의학회지
    • /
    • 제29권4호
    • /
    • pp.271-276
    • /
    • 2012
  • 사람에 연구에 따르면 심부전 진단에 널리 사용되는 NT-proBNP농도는 비만, 비만 관련인자들과 밀접한 상관 관계가 있는 것으로 알려져 있다. 그러나 이러한 상관관계는 아직까지 수의분야에서는 입증된 바가 없다. 따라서 본 연구에서는 다양한 정도의 이첨판 패쇄부전증(CMVI)에 이환된 73마리 개 집단에서 NT-proBNP와 비만 및 비만 관련인자들간의 상호관계를 조사하였다. 절식시 혈당 농도, 지방관련 인자(i.e., total triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C]), fructosamine, insulin 및 NT-proBNP 농도를 측정하였다. Insulin/glucose ratio 역시 계산하였다. NT-proBNP 농도는 CMVI에 의한 심부전의 정도에 따라 농도변화가 관찰되었으며, body condition scores (BCS), insulin 및 fructosamine 농도와도 관련이 있었다. 또한 본 연구를 통해 비만과 혈중 NT-proBNP농도 간에 상관관계 역시 확인되었다. 또한 NT-proBNP농도는 비만과 관련 있는 인자인 fructosamine과 insulin농도와도 관련이 있었다. 본 연구는 개에서 NT-proBNP농도와 비만 정도와 상관관계를 입증한 첫 보고이다.

만성 심부전 환자의 약물복용 이행 영향요인 (Factors Affecting Medication Adherence in Patients with Chronic Heart Failure)

  • 추상희;고일선;이원희;유지수;강석민;정하윤;김두리;안지현;이윤주
    • Journal of Korean Biological Nursing Science
    • /
    • 제14권3호
    • /
    • pp.193-202
    • /
    • 2012
  • Purpose: The purpose of this study was to explore socio-demographic, clinical and psychological factors associated with medication adherence among patients with chronic heart failure (CHF). Methods: In a cross-sectional survey, 133 patients with CHF who had visited a clinic located in Seoul participated. Medication adherence (MA) was measured using a single item visual analogue rating scale (VAS). Barriers and attitudes toward adherence, and depression were measured using a structured questionnaire. Medical records were reviewed to identify their clinical characteristics. Multivariate logistic regression was performed identify factors affecting medication adherence. Results: About one third of participants (31.1%) reported their MA as 100%. Overall attitudes on MA were highly positive and 49 (36.8%) of participants were depressive. MA was associated with significantly barriers (p<.001), attitudes (p<.001), age (p<.001), and duration of disease (p<.001). The high adherent group had significantly less barriers than other groups (OR=.389, p=0.02). Conclusion: This study indicates that barriers and attitudes toward MA were the most important factors affecting their adherence to HF medication. To improve MA for patient with CHF, the nursing strategies which can lead poor adherent patients to their optimal level should be developed.

식회화된 심낭 고리에 의한 심부전즙 - 1예 보고 (Heart Failure by a Calcific Pericardial Ring -A case report -)

  • 홍성범;안병희;류상완;정인석;김상형
    • Journal of Chest Surgery
    • /
    • 제38권9호
    • /
    • pp.648-651
    • /
    • 2005
  • 석회화된 수축성 심낭염은 만성 염증에 대한 비특이적 반응으로 여겨진다. 원인은 결핵에 의한 경우가 대부분이지만, 최근 결핵이 감소하면서 이러한 형태의 심낭염은 점점 감소하는 추세이다. 이 질환의 다른 원인으로는 방사선 치료, 류마티스성 질환, 유육종증, 그리고 외상 등이 있다. 결국 수축성심낭염은 원인이 무엇이든지간에 심장 이완기의 혈액 충만이 감소함으로써 심낭 압전에 이를 수 있다. 저자들은 최근 석회화된 심낭 고리에 의해 심부전을 일으킨 수축성 심낭염 환자를 치험하였기에 보고하는 바이다.

Results of Protocol-based Perioperative Management in Off-Pump Coronary Artery Bypass Grafting for Patients with Non-dialysis-dependent Chronic Kidney Disease

  • Kim, Jeong-Won;Sim, Hyung Tae;Yoo, Jae Suk;Kim, Dong Jin;Cho, Kwang Ree
    • Journal of Chest Surgery
    • /
    • 제49권6호
    • /
    • pp.427-434
    • /
    • 2016
  • Background: Recent studies have demonstrated the benefits of off-pump coronary bypass grafting over the on-pump technique in patients with chronic kidney disease (CKD). To further reduce the risk of acute kidney injury and the need for renal replacement therapy, even in patients undergoing off-pump coronary artery bypass grafting, we adopted protocol-based perioperative management for patients with CKD. Methods: From December 2012 to March 2015, 265 patients underwent isolated off-pump coronary artery bypass grafting. To analyze renal function in a stable condition, we excluded 12 dialysis-dependent end stage renal failure and 10 emergency or urgent cases. Among the remaining 243 patients, 208 patients had normal kidney function (normal group), and 35 patients had CKD (CKD group). Minimizing contrast exposure, ensuring adequate hydration, using strict drug dosage adjustment, and optimizing hemodynamic status were key elements of the protocol for the CKD group. Results: The risk of acute kidney injury was about ${\times}3$ higher in the CKD group than in the normal group (p=0.01). Estimated glomerular filtration rates and serum creatinine levels deteriorated until the third postoperative day in the CKD group. However, by adopting protocol-based perioperative management, this transient renal dysfunction recovered to preoperative levels by the fifth postoperative day without requiring renal replacement therapy in all cases. Conclusion: Off-pump coronary bypass surgery combined with this protocol-based perioperative management strategy in patients with non-dialysis-dependent CKD could mostly be performed without renal replacement therapy.